tiprankstipranks
Codexis Reports Strong Q3 Revenue Growth
Company Announcements

Codexis Reports Strong Q3 Revenue Growth

Codexis ( (CDXS) ) has released its Q3 earnings. Here is a breakdown of the information Codexis presented to its investors.

Don't Miss our Black Friday Offers:

Codexis, Inc., a prominent name in enzymatic solutions for therapeutics manufacturing, leverages its proprietary technology to enhance enzyme performance, primarily serving the pharmaceutical manufacturing sector. The company’s recent earnings report highlights a productive third quarter with strong revenue growth, strategic management appointments, and a significant cash influx extending their financial runway into 2027. Codexis reported a total revenue of $12.8 million for the third quarter of 2024, marking an increase from $9.3 million in the same period of 2023. Product revenues nearly doubled, reaching $11.2 million, attributed to the timing of customer orders, while the company also noted a decrease in R&D revenues. A notable financial achievement was narrowing their net loss to $20.6 million from $34.9 million year-over-year, with a cash position robust enough to fund operations into 2027. Looking ahead, Codexis remains focused on expanding its pharmaceutical manufacturing business and expects to announce its first technical collaboration with a major pharmaceutical partner by the end of the year, signaling potential growth and innovation in its enzymatic synthesis capabilities.

Related Articles
TipRanks Auto-Generated NewsdeskCodexis Strengthens Board and Updates Bylaws
TheFlyCodexis reports Q3 EPS (29c), consensus (24c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App